Sarver Vrooman Wealth Advisors’s Gilead Sciences GILD Stock Holding History

Sarver Vrooman Wealth Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$78.9K	Hold	613	–	–	0.05%	37
2026 Q1	$85.4K	Hold	613	–	–	0.05%	33
2025 Q4	$75.2K	Sell	613 -16	-3%	-$1.94K	0.05%	33
2025 Q3	$69.8K	Hold	629	–	–	0.04%	48
2025 Q2	$69.7K	Hold	629	–	–	0.05%	44
2025 Q1	$70.5K	Buy	+629	New	+$64.9K	0.05%	59

Other funds holding GILD

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

CIM

Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

CGH

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Sarver Vrooman Wealth Advisors's GILD Position: Q2 2026 in Review

Sarver Vrooman Wealth Advisors held its Gilead Sciences (GILD) position steady in Q2 2026 at 613 shares worth $78.9K. The position accounts for 0.05% of the portfolio, ranked #37.

Sarver Vrooman Wealth Advisors first reported a position in GILD in Q1 2025 and has held it in 6 quarters since. The position peaked at $85.4K in Q1 2026. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Sarver Vrooman Wealth Advisors held 613 shares of Gilead Sciences worth $78.9K as of Q2 2026.
Sarver Vrooman Wealth Advisors left its Gilead Sciences share count unchanged in Q2 2026.
Gilead Sciences made up 0.05% of Sarver Vrooman Wealth Advisors's portfolio in Q2 2026, its #37 holding.
Sarver Vrooman Wealth Advisors first reported a position in Gilead Sciences in Q1 2025 and has held it in 6 quarters since.
Sarver Vrooman Wealth Advisors's Gilead Sciences position peaked at $85.4K in Q1 2026.
690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Sarver Vrooman Wealth Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.